Migraine Emerging and Marketed Drugs Assessment (2023 Updates) | Clinical and Non-Clinical Trials Evaluation, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies

Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, about 30+ key pharma and biotech companies are working on 30+ pipeline drugs in the Migraine therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

“Migraine Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Migraine Market.

The Migraine Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Migraine Pipeline Analysis
The report provides insights into:
– The report provides detailed insights about emerging therapies for the treatment of Migraine and the aggregate therapies developed by major pharma companies.
– It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Migraine Treatment.
– It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
– The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
– It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Migraine market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Delveinsight’s Report Covers Emerging Products Under Different Phases of Clinical Development Like –
– Late-stage products (Phase III)
– Mid-stage products (Phase II)
– Early-stage products (Phase I/II and Phase I)
– Pre-clinical and Discovery stage candidates
– Discontinued & Inactive candidates

Route of Administration
Migraine pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
– Intra-articular
– Intraocular
– Intrathecal
– Intravenous
– Ophthalmic
– Oral
– Parenteral
– Subcutaneous
– Topical
– Transdermal

Molecule Type
Products have been categorized under various Molecule types, such as
– Oligonucleotide
– Peptide
– Small molecule

Migraine Therapeutics Landscape

Several major pharma and biotech giants are developing therapies for Migraine. Currently, Novartis is leading the therapeutics market with its Migraine drug candidates in the most advanced stage of clinical development.

Some of the key companies in the Migraine Therapeutics Market include:

AbbVie, AEON Biopharma, Aeon Biopharma Inc., Allergan, Allodynic Therapeutics, Amgen, Autonomic Technologies, Inc., Axsome Therapeutics, Biohaven Pharmaceuticals, Boston Scientific, Cefaly Technology, Charleston Laboratories, Chordate Medical, Dr. Reddy’s Labs, ElectroCore, INC, Eli Lilly and Company, eNeura, Inc., Impel NeuroPharma, Ionis Pharmaceuticals, Inc., Lundbeck Seattle BioPharmaceutical, Neurolief Ltd., Nocira, LLC, Novartis, Pear Therapeutics, Pharmaleads, Pulmatrix, Salvia BioElectronics, Satsuma Pharmaceuticals, Shiratronics Inc., Soterix Medical, Stimwave Technologies, Teva Pharmaceuticals, Theranica Bio-Electronic Ltd., Tonix Pharmaceuticals, Trevena, tVNS technologies GmbH, Unity HA, Vaxxinity, WAT Medical, Xoc Pharmaceuticals, Zosano Pharma, and many others.

Migraine Therapies covered in the report include:

– AXS-07: Axsome Therapeutics
– STS-101: Satsuma Pharmaceuticals
– Zavegepant: Biohaven Pharmaceuticals
– TNX1900: Tonix Pharmaceuticals
– INP104: Impel NeuroPharma
And many more

Explore More About the Emerging Drugs and Key Companies @ https://www.delveinsight.com/sample-request/migraine-pipeline-insight

Table of Content (TOC)

1. Report Introduction
2. Executive Summary
3. Migraine Current Treatment Patterns
4. Migraine – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Migraine Late-Stage Products (Phase-III)
7. Migraine Mid-Stage Products (Phase-II)
8. Migraine Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Migraine Discontinued Products
13. Migraine Product Profiles
14. Key Companies in the Migraine Market
15. Key Products in the Migraine Therapeutics Segment
16. Dormant and Discontinued Products
17. Migraine Unmet Needs
18. Migraine Future Perspectives
19. Migraine Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Get a Detailed Assessment into the Ongoing Clinical and Regulatory Development Activities @ https://www.delveinsight.com/sample-request/migraine-pipeline-insight

Contact Info:
Shruti Thakur
Manager (Marketing and Branding)
Email: info@delveinsight.com

Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.